Literature DB >> 27841848

NONDAMAGING RETINAL LASER THERAPY FOR TREATMENT OF CENTRAL SEROUS CHORIORETINOPATHY: What is the Evidence?

Edward H Wood1, Peter A Karth, Steven R Sanislo, Darius M Moshfeghi, Daniel V Palanker.   

Abstract

PURPOSE: To summarize the literature addressing subthreshold or nondamaging retinal laser therapy (NRT) for central serous chorioretinopathy (CSCR) and to discuss results and trends that provoke further investigation.
METHODS: Analysis of current literature evaluating NRT with micropulse or continuous wave lasers for CSCR.
RESULTS: Sixteen studies including 398 patients consisted of retrospective case series, prospective nonrandomized interventional case series, and prospective randomized clinical trials. All studies but one evaluated chronic CSCR, and laser parameters varied greatly between studies. Mean central macular thickness decreased, on average, by ∼80 μm by 3 months. Mean best-corrected visual acuity increased, on average, by about 9 letters by 3 months, and no study reported a decrease in acuity below presentation. No retinal complications were observed with the various forms of NRT used, but six patients in two studies with micropulse laser experienced pigmentary changes in the retinal pigment epithelium attributed to excessive laser settings.
CONCLUSION: Based on the current evidence, NRT demonstrates efficacy and safety in 12-month follow-up in patients with chronic and possibly acute CSCR. The NRT would benefit from better standardization of the laser settings and understanding of mechanisms of action, as well as further prospective randomized clinical trials.

Entities:  

Mesh:

Year:  2017        PMID: 27841848     DOI: 10.1097/IAE.0000000000001386

Source DB:  PubMed          Journal:  Retina        ISSN: 0275-004X            Impact factor:   4.256


  18 in total

1.  Visual outcomes and anatomic changes after sub-threshold micropulse yellow laser (577-nm) treatment for chronic central serous chorioretinopathy: long-term follow-up.

Authors:  A Arsan; H S Kanar; A Sonmez
Journal:  Eye (Lond)       Date:  2018-01-05       Impact factor: 3.775

2.  Efficacy of the subthreshold micropulse yellow wavelength laser photostimulation in the treatment of chronic central serous chorioretinopathy.

Authors:  Mehmed Uğur Işık; Mehmet Fatih Kağan Değirmenci; Ayhan Sağlık
Journal:  Int J Ophthalmol       Date:  2020-09-18       Impact factor: 1.779

Review 3.  [Statement and recommendation of the Professional Association of German Ophthalmologists (BVA), the German Ophthalmological Society (DOG) and the German Retina Society (RG) on central serous chorioretinopathy : Situation January 2018].

Authors: 
Journal:  Ophthalmologe       Date:  2018-05       Impact factor: 1.059

4.  Subretinal fibrin absorption after 577-nm subthreshold micropulse laser therapy in a CSC case: a brief report.

Authors:  Lijun Zhou; Tao Li; Kunbei Lai; Chuangxin Huang; Fabao Xu; Zhe Zhu; Lin Lu; Chenjin Jin
Journal:  Lasers Med Sci       Date:  2017-09-05       Impact factor: 3.161

5.  Navigated laser photocoagulation in patients with non-resolving and chronic central serous chorioretinopathy.

Authors:  Bert Müller; Janina Tatsios; Jan Klonner; Daniel Pilger; Antonia M Joussen
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2018-06-06       Impact factor: 3.117

Review 6.  [Statement of the Professional Association of Ophthalmologists in Germany (BVA), the German Ophthalmological Society (DOG) and the Retinological Society (RG) on central serous chorioretinopathy : Status 18 October 2021].

Authors: 
Journal:  Ophthalmologe       Date:  2021-12-14       Impact factor: 1.059

Review 7.  Statement of the Professional Association of Ophthalmologists in Germany (BVA), the German Society of Ophthalmology (DOG) and the German Retina Society (RG) on central serous chorioretinopathy : Status 18 October 2021.

Authors: 
Journal:  Ophthalmologie       Date:  2022-04-06

Review 8.  Non-resolving, recurrent and chronic central serous chorioretinopathy: available treatment options.

Authors:  Francesco Sartini; Michele Figus; Marco Nardi; Giamberto Casini; Chiara Posarelli
Journal:  Eye (Lond)       Date:  2019-03-01       Impact factor: 3.775

Review 9.  [Central serous chorioretinopathy].

Authors:  Laurenz Pauleikhoff; Hansjürgen Agostini; Clemens Lange
Journal:  Ophthalmologe       Date:  2021-04-16       Impact factor: 1.059

10.  Selective Retina Therapy with Real-Time Feedback-Controlled Dosimetry for Treating Acute Idiopathic Central Serous Chorioretinopathy in Korean Patients.

Authors:  Ye Ji Kim; Youn Gon Lee; Dong Won Lee; Jae Hui Kim
Journal:  J Ophthalmol       Date:  2018-02-06       Impact factor: 1.909

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.